Aquestive Therapeutics Inc (AQST) deserves closer scrutiny

While Aquestive Therapeutics Inc has overperformed by 3.51%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AQST rose by 25.98%, with highs and lows ranging from $5.80 to $2.12, whereas the simple moving average fell by -3.47% in the last 200 days.

On June 02, 2025, Oppenheimer started tracking Aquestive Therapeutics Inc (NASDAQ: AQST) recommending Outperform. A report published by Cantor Fitzgerald on December 17, 2024, Initiated its previous ‘Overweight’ rating for AQST. Leerink Partners also rated AQST shares as ‘Outperform’, setting a target price of $8 on the company’s shares in an initiating report dated May 10, 2024. Piper Sandler Initiated an Overweight rating on April 11, 2024, and assigned a price target of $10. Raymond James initiated its ‘Outperform’ rating for AQST, as published in its report on March 28, 2024. RBC Capital Mkts’s report from April 07, 2021 suggests a price prediction of $7 for AQST shares, giving the stock a ‘Outperform’ rating. H.C. Wainwright also rated the stock as ‘Buy’.

Analysis of Aquestive Therapeutics Inc (AQST)

Further, the quarter-over-quarter decrease in sales is -27.65%, showing a negative trend in the upcoming months.

Aquestive Therapeutics Inc’s future performance can be predicted by a variety of well-rounded types of analysis and research, with equity being one of the most crucial ones. Taking into account the quick ratio of the company, currently set at 4.48, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.

For any stock, average volume can be an extremely valuable indicator of volatility, and AQST is registering an average volume of 1.50M. Furthermore, long-term investors anticipate a median target price of $8.42, showing growth from the present price of $3.54, which can serve as yet another indication of whether AQST is worth investing in or should be passed over.

How Do You Analyze Aquestive Therapeutics Inc Shares?

Besides checking the fundamentals, you should also know how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 7.70%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 42.63% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.

AQST shares are owned by institutional investors to the tune of 42.63% at present.

Hot this week

Is Reviva Pharmaceuticals Holdings Inc (RVPH) a good investment opportunity?

While Reviva Pharmaceuticals Holdings Inc has underperformed by -0.20%,...

VivoPower International PLC (VVPR) presents a great opportunity, but the stock is slightly overvalued

While VivoPower International PLC has overperformed by 15.08%, investors...

Is it possible to buy Nektar Therapeutics(NKTR) shares at a good price now?

While Nektar Therapeutics has underperformed by -0.36%, investors are...

Examining Mustang Bio Inc (MBIO) stock is warranted

While Mustang Bio Inc has underperformed by -1.12%, investors...

E.W. Scripps Co (SSP)’s results reveal risk

While E.W. Scripps Co has underperformed by -9.40%, investors...

Topics

Is Reviva Pharmaceuticals Holdings Inc (RVPH) a good investment opportunity?

While Reviva Pharmaceuticals Holdings Inc has underperformed by -0.20%,...

VivoPower International PLC (VVPR) presents a great opportunity, but the stock is slightly overvalued

While VivoPower International PLC has overperformed by 15.08%, investors...

Is it possible to buy Nektar Therapeutics(NKTR) shares at a good price now?

While Nektar Therapeutics has underperformed by -0.36%, investors are...

Examining Mustang Bio Inc (MBIO) stock is warranted

While Mustang Bio Inc has underperformed by -1.12%, investors...

E.W. Scripps Co (SSP)’s results reveal risk

While E.W. Scripps Co has underperformed by -9.40%, investors...

Was there any good news for Centrus Energy Corp (LEU) stock in the last session?

While Centrus Energy Corp has overperformed by 4.53%, investors...

It would be worthwhile to take a closer look at Complete Solaria Inc (SPWR)

While Complete Solaria Inc has underperformed by -6.70%, investors...

The Evoke Pharma Inc (EVOK) had a good session last reading, didn’t it?

While Evoke Pharma Inc has underperformed by -1.64%, investors...
spot_img

Related Articles

Popular Categories

spot_imgspot_img
US Post News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.